Read Gene

Read Gene Equity Ratio

The Equity Ratio of Read Gene (RDG.WA) as of Oct 16, 2026 is 20.40 %. In the previous year, Equity Ratio was 20.53 % — a change of -0.64% (lower).

Equity Ratio

20.40 %

YoY

-0.64%

Last updated:

Equity Ratio of Read Gene is 2025 20.40 % . Equity Ratio of Read Gene was 2024 20.53 % . It decreases by -0.64% lower compared to the previous year.

The Read Gene Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
20.01 PLN
Jan 1, 2019
21.43 PLN
Jan 1, 2020
20.63 PLN
Jan 1, 2021
35.20 PLN
Jan 1, 2022
35.22 PLN
Jan 1, 2023
27.52 PLN
Jan 1, 2024
20.53 PLN
Jan 1, 2025
20.40 PLN
The Read Gene Equity Ratio history
YEAREquity RatioYoY
20.40 %-0.64%
20.53 %-25.38%
27.52 %-21.86%
35.22 %+0.04%
35.20 %+70.60%
20.63 %-3.70%
21.43 %+7.06%
20.01 %+46.52%
13.66 %-17.61%
16.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA is a biotechnology company based in Szczecin, Poland, operating within the Health Care sector. The company went public via an IPO on February 12, 2009, and is listed under the ticker RDG.WA with ISIN PLRADGN00014. Read Gene SA focuses on medical research and testing, particularly in the fields of chemoprevention, clinical trials, and genetic testing. Its services include specialized tests for breast cancer, colon cancer, and prostate cancer, alongside medical consultancy and DNA testing. The company also provides DNA-related supplements. It operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o., and its major shareholder is GEN-PAT-MED Sp. z o.o. The company's headquarters are located in Szczecin, within the West Pomeranian Voivodeship. Read Gene SA's activities are centered on developing technologies aimed at detecting, preventing, and treating malignant tumors. The company's website is https://read-gene.com/. No additional details regarding founding year, specific products, or financial figures are provided in the source material. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Equity Ratio of Read Gene is 20.40 % in 2025.

Equity Ratio of Read Gene changed from 20.53 % to 20.40 %, representing a -0.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Read Gene since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Read Gene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Read Gene

All Key Metrics — Read Gene